Q J Med 1994; 87: 671-678
© 1994 Association of Physicians
research-article |
Birmingham Vasculitis Activity Score (BVAS) Dim system necrotizinig vasculitis
From the Departments of Rheumatology Edgbaston, West Midlands, UK 1From the Nephrology, University of Birmingham Edgbaston, West Midlands, UK
Address correspondence to Professor P.A. Bacon, Department of Rheumatology, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT
Received 25 March 1994 Accepted for publication 4 May 1994.
The continuing morbidity of patients with vasculitis despite the improved prognosis with aggressive therapy, underlines the need for accurate disease assessment We have devised a clinical index of disease activity, and evaluated its use in several forms of necrotizing vasculitis. The weighted score is based on symptoms and signs in nine separate organ systems. Disease features are only scored if they are attributable to active vasculitis. The Birmingham Vasculitis Activity Score (BVAS) was compared with two other published vasculitis activity scores, with the physician's global assessment (PGA), with outcome, and with serological markers of disease activity. In a cross-sectional study of 213 consecutive patients with different forms of vasculitis, all 107 vasculitis patients who were judged completely well on clinical assessment had a BVAS score of 0. Twenty-two patients with active vasculitis prior to treatment had a median score of 7.5 (range 4–30) and 69 with active disease on treatment had a median score of 10 (1–29). Of the 12 who died, median score immediately prior to death was 20.5 (9–30). In a serial prospective study, 30 cases had documented episodes of active disease. During periods of disease activity, the median BVAS values were significantly higher than in remission (15 [range 3–32] vs. 0 [0–2], p < 0.001); the same was true for CRP values (80 [9–361] vs. 13.5 [5–68], p < 0.001). This was not true for erythrocyte sedimentation rate (ESR), haemoglobin (Hb) or von Willebrand factor (VWF). In three patients with clinically active disease requiring change of therapy, BVAS was elevated whereas the CRP remained < 20; in nine patients in clinical remission, BVAS was < 2 whilst CRP remained > 20. BVAS had low inter-observer variability, and agreed significantly with two other indices of disease activity. This clinical activity index allows precise assessment of organ involvement in vasculitis compared to a global assessment, whilst the cumulative index provides a useful standard by which to assess serological markers and the need for further therapy.
* Present address: Dr R.A. Luqmani, Regional and Academic Rheumatology Unit, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L Josselin, A Mahr, P Cohen, C Pagnoux, G Guaydier-Souquieres, G Hayem, C Job-Deslandre, F Liferman, J Pourrat, and L Guillevin Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients Ann Rheum Dis, September 1, 2008; 67(9): 1343 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X Puechal, C Miceli-Richard, O Mejjad, P Lafforgue, C Marcelli, E Solau-Gervais, S Steinfeld, C Villoutreix, R Treves, X Mariette, et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis Ann Rheum Dis, June 1, 2008; 67(6): 880 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Flossmann, P Bacon, K de Groot, D Jayne, N Rasmussen, P Seo, K Westman, and R Luqmani Development of comprehensive disease assessment in systemic vasculitis Postgrad. Med. J., March 1, 2008; 84(989): 143 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Bjerkeli, J. K. Damas, B. Fevang, J. C. Holter, P. Aukrust, and S. S. Froland Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis possible role in vascular inflammation Rheumatology, September 1, 2007; 46(9): 1422 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R.W. Jayne, G. Gaskin, N. Rasmussen, D. Abramowicz, F. Ferrario, L. Guillevin, E. Mirapeix, C. O.S. Savage, R. A. Sinico, C. A. Stegeman, et al. Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2180 - 2188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Metzler, N. Miehle, K. Manger, C. Iking-Konert, K. de Groot, B. Hellmich, W. L. Gross, E. Reinhold-Keller, and for the German Network of Rheumatic Diseases Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis Rheumatology, July 1, 2007; 46(7): 1087 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. GUILPAIN, J.-F. AUCLAIR, M. C. TAMBY, A. SERVETTAZ, A. MAHR, B. WEILL, L. GUILLEVIN, and L. MOUTHON Serum Eosinophil Cationic Protein: A Marker of Disease Activity in Churg-Strauss Syndrome Ann. N.Y. Acad. Sci., June 1, 2007; 1107(1): 392 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Stassen, J. W. Cohen Tervaert, and C. A Stegeman Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide Ann Rheum Dis, June 1, 2007; 66(6): 798 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Mukhtyar, D. Boumpas, C. Gordon, W. Gross, D. Jayne, and R. Luqmani Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus Ann Rheum Dis, May 1, 2007; 66(5): 569 - 570. [Full Text] [PDF]
|
|
|
|
|
|
B. Hellmich, O. Flossmann, W. L Gross, P. Bacon, J. Willem Cohen-Tervaert, L. Guillevin, D. Jayne, A. Mahr, P. A Merkel, H. Raspe, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis Ann Rheum Dis, May 1, 2007; 66(5): 605 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Khan, M. R. Subla, D. Behl, U. Specks, and B. Afessa Outcome of Patients With Small-Vessel Vasculitis Admitted to a Medical ICU Chest, April 1, 2007; 131(4): 972 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Hogan, G. S. Cooper, D. A. Savitz, L. A. Nylander-French, C. G. Parks, H. Chin, C. E. Jennette, S. Lionaki, J. C. Jennette, and R. J. Falk Association of Silica Exposure with Anti-Neutrophil Cytoplasmic Autoantibody Small-Vessel Vasculitis: A Population-Based, Case-Control Study Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 290 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Flossmann, P. Bacon, K. de Groot, D. Jayne, N. Rasmussen, P. Seo, K. Westman, and R. Luqmani Development of comprehensive disease assessment in systemic vasculitis Ann Rheum Dis, March 1, 2007; 66(3): 283 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chen, F. Yu, S.-X. Wang, W.-Z. Zou, M.-H. Zhao, and H.-Y. Wang Antineutrophil Cytoplasmic Autoantibody-Negative Pauci-immune Crescentic Glomerulonephritis J. Am. Soc. Nephrol., February 1, 2007; 18(2): 599 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Selga, A. Mohammad, G. Sturfelt, and M. Segelmark Polyarteritis nodosa when applying the Chapel Hill nomenclature--a descriptive study on ten patients Rheumatology, October 1, 2006; 45(10): 1276 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Huugen, J. W. Cohen Tervaert, and P. Heeringa TNF-{alpha} Bioactivity-Inhibiting Therapy in ANCA-Associated Vasculitis: Clinical and Experimental Considerations Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1100 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Flossmann, R B Jones, D R W Jayne, and R A Luqmani Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis, July 1, 2006; 65(7): 841 - 844. [Full Text] [PDF]
|
|
|
|
|
|
P M Aries, B Hellmich, J Voswinkel, M Both, B Nolle, K Holl-Ulrich, P Lamprecht, and W L Gross Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations Ann Rheum Dis, July 1, 2006; 65(7): 853 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Raza, D M Carruthers, R Stevens, A D Filer, J N Townend, and P A Bacon Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis Ann Rheum Dis, July 1, 2006; 65(7): 946 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Suresh, D Wong, S Kamali, C Hall, and R Luqmani An unusual cause of death in Wegener's granulomatosis. Ann Rheum Dis, May 1, 2006; 65(5): 698 - 698. [Full Text] [PDF]
|
|
|
|
|
|
A Woywodt, C Goldberg, T Kirsch, K de Groot, U Erdbruegger, H Haller, and M Haubitz Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA associated vasculitis Ann Rheum Dis, February 1, 2006; 65(2): 164 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Keogh, S. R. Ytterberg, F. C. Fervenza, K. A. Carlson, D. R. Schroeder, and U. Specks Rituximab for Refractory Wegener's Granulomatosis: Report of a Prospective, Open-Label Pilot Trial Am. J. Respir. Crit. Care Med., January 15, 2006; 173(2): 180 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sable-Fourtassou, P. Cohen, A. Mahr, C. Pagnoux, L. Mouthon, D. Jayne, D. Blockmans, J.-F. Cordier, P. Delaval, X. Puechal, et al. Antineutrophil Cytoplasmic Antibodies and the Churg-Strauss Syndrome Ann Intern Med, November 1, 2005; 143(9): 632 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Holmen, E. Elsheikh, P. Stenvinkel, A. R. Qureshi, E. Pettersson, S. Jalkanen, and S. Sumitran-Holgersson Circulating Inflammatory Endothelial Cells Contribute to Endothelial Progenitor Cell Dysfunction in Patients with Vasculitis and Kidney Involvement J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3110 - 3120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. SINICO, A. RADICE, C. CORACE, L. DI TOMA, and E. SABADINI Value of a New Automated Fluorescence Immunoassay (EliA) for PR3 and MPO-ANCA in Monitoring Disease Activity in ANCA-Associated Systemic Vasculitis Ann. N.Y. Acad. Sci., June 1, 2005; 1050(1): 185 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Schmitt, R. Birck, P. A. Heinzel, U. Gobel, M. Choi, K. Warnatz, H. H. Peter, and F. J. van der Woude Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1083 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K de Leeuw, J-S Sanders, C Stegeman, A Smit, C G Kallenberg, and M Bijl Accelerated atherosclerosis in patients with Wegener's granulomatosis Ann Rheum Dis, May 1, 2005; 64(5): 753 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Bjerkeli, B Halvorsen, J K Damas, I Nordoy, A Yndestad, P Aukrust, and S S Froland Expression of matrix metalloproteinases in patients with Wegener's granulomatosis Ann Rheum Dis, December 1, 2004; 63(12): 1659 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.D. Booth, D.R.W. Jayne, R.K. Kharbanda, C.M. McEniery, I.S. Mackenzie, J. Brown, and I.B. Wilkinson Infliximab Improves Endothelial Dysfunction in Systemic Vasculitis: A Model of Vascular Inflammation Circulation, April 13, 2004; 109(14): 1718 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jayne, N. Rasmussen, K. Andrassy, P. Bacon, J. W. C. Tervaert, J. Dadoniene, A. Ekstrand, G. Gaskin, G. Gregorini, K. de Groot, et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies N. Engl. J. Med., July 3, 2003; 349(1): 36 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D Filer, J M Gardner-Medwin, J Thambyrajah, K Raza, D M Carruthers, R J Stevens, L Liu, S E Lowe, J N Townend, and P A Bacon Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa Ann Rheum Dis, February 1, 2003; 62(2): 162 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D Booth, H J Jefferson, W Ayliffe, P A Andrews, and D R Jayne Safety and efficacy of TNF{alpha} blockade in relapsing vasculitis Ann Rheum Dis, June 1, 2002; 61(6): 559 - 559. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Komocsi, P. Lamprecht, E. Csernok, A. Mueller, K. Holl-Ulrich, U. Seitzer, F. Moosig, A. Schnabel, and W. L. Gross Peripheral Blood and Granuloma CD4+CD28- T Cells Are a Major Source of Interferon-{gamma} and Tumor Necrosis Factor-{alpha} in Wegener's Granulomatosis Am. J. Pathol., May 1, 2002; 160(5): 1717 - 1724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koldingsnes and H. Nossent Predictors of survival and organ damage in Wegener's granulomatosis Rheumatology, May 1, 2002; 41(5): 572 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Fraenkel-Rubin, D Ergas, and Z M Sthoeger Limited polyarteritis nodosa of the male and female reproductive systems: diagnostic and therapeutic approach Ann Rheum Dis, April 1, 2002; 61(4): 362 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Wilson, G. D. Kitas, D. M. Carruthers, C. Reay, J. Skan, S. Harris, G. J. Treharne, S. P. Young, and P. A. Bacon Computerized information-gathering in specialist rheumatology clinics: an initial evaluation of an electronic version of the Short Form 36 Rheumatology, March 1, 2002; 41(3): 268 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Lamprecht, F Moosig, E Csernok, U Seitzer, A Schnabel, A Mueller, and W L Gross CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis Thorax, October 1, 2001; 56(10): 751 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Bowman, S. Pillemer, R. Jonsson, K. Asmussen, C. Vitali, R. Manthorpe, and N. Sutcliffe Revisiting Sjogren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK Rheumatology, October 1, 2001; 40(10): 1180 - 1188. [Full Text] [PDF]
|
|
|
|
|
|
R. Nowack, I. Grab, L.-F. Flores-Suarez, P. Schnulle, B. Yard, and F. J. van der Woude ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1631 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mahr, T. Girard, R. Agher, and L. Guillevin Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up Rheumatology, May 1, 2001; 40(5): 492 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Lamprecht, F Moosig, A Gause, K Herlyn, E Csernok, H Hansen, and W L Gross Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis Ann Rheum Dis, April 1, 2001; 60(4): 385 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Raza, J. Thambyrajah, J. N. Townend, A. R. Exley, C. Hortas, A. Filer, D. M. Carruthers, and P. A. Bacon Suppression of Inflammation in Primary Systemic Vasculitis Restores Vascular Endothelial Function: Lessons for Atherosclerotic Disease? Circulation, September 26, 2000; 102(13): 1470 - 1472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A Brogan and M J Dillon Personal practice: The use of immunosuppressive and cytotoxic drugs in non-malignant disease Arch. Dis. Child., September 1, 2000; 83(3): 259 - 264. [Full Text] [PDF]
|
|
|
|
 |
|
 D.R.W. Jayne, H. Chapel, D. Adu, S. Misbah, D. O'Donoghue, D. Scott, and C.M. Lockwood Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity QJM, July 1, 2000; 93(7): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Sørensen, O. Slot, N. Tvede, and J. Petersen A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature Ann Rheum Dis, June 1, 2000; 59(6): 478 - 482. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Watts, D. G. I. Scott, C. D. Pusey, and C. M. Lockwood Vasculitis--aims of therapy. An overview Rheumatology, March 1, 2000; 39(3): 229 - 232. [Full Text] [PDF]
|
|
|
|
|
|
W. L. Gross, A. Trabandt, and E. Reinhold-Keller Diagnosis and evaluation of vasculitis Rheumatology, March 1, 2000; 39(3): 245 - 252. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Lane, D. G. I. Scott, A. Heaton, and R. A. Watts Primary renal vasculitis in Norfolk--increasing incidence or increasing recognition? Nephrol. Dial. Transplant., January 1, 2000; 15(1): 23 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. NOWACK, U. GÖBEL, P. KLOOKER, O. HERGESELL, K. ANDRASSY, and F. J. VAN DER WOUDE Mycophenolate Mofetil for Maintenance Therapy of Wegener's Granulomatosis and Microscopic Polyangiitis: A Pilot Study in 11 Patients with RenalInvolvement J. Am. Soc. Nephrol., September 1, 1999; 10(9): 1965 - 1971. [Abstract] [Full Text]
|
|
|
|
|
|
C. F. M. FRANSSEN, M. G. HUITEMA, A. C. M. KOBOLD, W. W. OOST-KORT, P. C. LIMBURG, A. TIEBOSCH, C. A. STEGEMAN, C. G. M. KALLENBERG, and J. W. C. TERVAERT In Vitro Neutrophil Activation by Antibodies to Proteinase 3 and Myeloperoxidase from Patients with Crescentic Glomerulonephritis J. Am. Soc. Nephrol., July 1, 1999; 10(7): 1506 - 1515. [Abstract] [Full Text]
|
|
|
|
|
|
A. C M. Kobold, C. G M Kallenberg, and J. W. C. Tervaert Monocyte activation in patients with Wegener's granulomatosis Ann Rheum Dis, April 1, 1999; 58(4): 237 - 245. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Bradlow and J. David Recent Advances: Rheumatology BMJ, March 11, 1995; 310(6980): 637 - 640. [Full Text]
|
|